Status: Not yet recruiting
An Exploratory Clinical Study Of Bempemab Combined With Anlotinib As First-Line Treatment For Elderly Patients With Locally Advanced Or Metastatic Non-Small-Cell Lung Cancer
This exploratory clinical study evaluates the efficacy and safety of combining benmelstobart (a PD-L1 inhibitor) with anlotinib (a multi-target anti-angiogenic TKI) as a first-line, chemotherapy-free treatment for elderly patients with locally advanced or metastatic non-small cell lung cancer (NSCLC).
Participants needed: 30
Trial details
Age: 75+Biological sex: AllType: InterventionalSponsor: Zhejiang Cancer HospitalUpdated: Sep 30, 2026Locations: 1
Eligibility criteria
Not listed